Lumos Pharma Shares Outstanding 2009-2021 | LUMO

Lumos Pharma shares outstanding from 2009 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Lumos Pharma Annual Shares Outstanding
(Millions of Shares)
2020 7
2019 1
2018 4
2017 3
2016 3
2015 3
2014 3
2013 3
2012 2
2011 1
2010 0
2009 0
2008 1
2007 1
Lumos Pharma Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 9
2021-03-31 8
2020-12-31 7
2020-09-30 8
2020-06-30 8
2020-03-31 2
2019-12-31 4
2019-09-30 1
2019-06-30 1
2019-03-31 1
2018-12-31 4
2018-09-30 4
2018-06-30 4
2018-03-31 4
2017-12-31 3
2017-09-30 3
2017-06-30 3
2017-03-31 3
2016-12-31 3
2016-09-30 3
2016-06-30 3
2016-03-31 3
2015-12-31 3
2015-09-30 3
2015-06-30 3
2015-03-31 4
2014-12-31 3
2014-09-30 3
2014-06-30 3
2014-03-31 3
2013-12-31 3
2013-09-30 3
2013-06-30 3
2013-03-31 3
2012-12-31 2
2012-09-30 2
2012-06-30 2
2012-03-31 2
2011-12-31 1
2011-09-30 0
2011-06-30 0
2011-03-31 0
2010-12-31
2010-09-30 0
2009-12-31
2008-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.078B $0.000B
Lumos Pharma Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's product pipeline consists of LUM-201 which is in clinical stage. Lumos Pharma Inc., formerly known as NewLink Genetics Corporation, is based in AUSTIN, Texas.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57